NASH

[Scientific Reports] Scientists evaluated changes in urea cycle enzymes in non-alcoholic fatty liver disease (NAFLD) patients and in two preclinical animal models mimicking this entity. Seventeen liver specimens from NAFLD patients were included for immunohistochemistry and gene expression analysis.

[Nature Communications] Researchers identified the tripartite motif-containing protein 31 (Trim31) as an endogenous inhibitor of rhomboid 5 homolog 2 (Rhbdf2), and further determined that Trim31 directly bound to Rhbdf2 and facilitated its proteasomal degradation.

[Acta Pharmacologica Sinica] The authors review the functions of REV-ERB with regard to their relevance to non-alcoholic steatohepatitis (NASH) as well as the potential to target REV-ERB for treatment of this disease.

[Acta Pharmacologica Sinica] Scientists summarize the current knowledge on the role of bile acids and the receptors in the development of nonalcoholic fatty liver disease and nnonalcoholic steatohepatitis, especially the functions of farnesoid X receptor in different tissues including liver and intestine.

[Lancet Diabetes & Endocrinology] Investigators discuss how diabetes can affect the development of hepatic steatosis and its progression to advanced liver damage.

[Molecular Therapy] Scientists developed a new non-alcoholic fatty liver disease model oriented from a type 2 diabetes mellitus mouse, which spontaneously progressed to histological features of non-alcoholic steatohepatitis, fibrosis and HCC with high incidence.